FrankYung-ChinTsaiMD

Physician

Dr. Tsai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
9055 E Del Camino Dr
Ste 100
Scottsdale, AZ 85258
Phone+1 480-860-5000

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Stony Brook Medicine/University HospitalResidency, Internal Medicine, 2002 - 2005
Stony Brook University Health Sciences Center School of MedicineClass of 2002

PubMed

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Andrew J Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H Miller Jr
Investigational New Drugs. 2024-06-01
8 citations
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Andrew J Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H Miller Jr
Investigational New Drugs. 2024-02-01
29 citations
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
Jason J. Luke, Fabrice Barlesi, Ki Y. Chung, Anthony W. Tolcher, Karen Kelly
Journal for Immunotherapy of Cancer. 2021-02-01

Immersive Experiences Could Help Educate Patients, Cut down on Video Call FatigueJune 11th, 2020
First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research InstituteMarch 20th, 2019